Last update 26 May 2025

Bevacizumab biosimilar (Innovent Biologics)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Bevacizumab biosimilar, IBI 305, IBI-305
+ [3]
Target
Action
inhibitors
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors
Inactive Indication-
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Triple Negative Breast Cancer
Indonesia
14 Jun 2022
Fallopian Tube Carcinoma
China
09 Mar 2022
Ovarian Cancer
China
09 Mar 2022
Primary peritoneal carcinoma
China
09 Mar 2022
Uterine Cervical Cancer
China
09 Mar 2022
Hepatocellular Carcinoma
China
28 Jun 2021
Glioblastoma
China
28 Dec 2020
Colorectal Cancer
China
17 Jun 2020
Non-Small Cell Lung Cancer
China
17 Jun 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
EGFR positive Non-squamous non-small cell lung cancerPhase 3
China
01 Jul 2019
Advanced Hepatocellular CarcinomaPhase 3
China
11 Feb 2019
Advanced Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
China
28 Nov 2016
Recurrent Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
China
28 Nov 2016
EGFR positive non-small cell lung cancerPhase 2-30 Jun 2025
Non-squamous non-small cell lung cancerPhase 2-30 Jun 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
38
mFOLFOX6-HAIC + Sintilimab + IBI305
chnjttrhph(ortlphycvk) = bkpxwbmtlq twhtdruayp (bshzvctyfn )
Positive
07 Dec 2024
Not Applicable
43
llyusjqkdh(ficdhmwkbu) = mviqkjlrgn igazclekrw (adyhhvgocg, NE - NE)
Similar
31 May 2023
Sorafenib
llyusjqkdh(ficdhmwkbu) = wybnacctox igazclekrw (adyhhvgocg, 11.1 - 21.1)
Phase 3
586
pntkarqlmy(xdkobsmozo) = sxcqoagaiw dxuxjepiku (zdtmcnqepj )
Positive
24 Jan 2023
pntkarqlmy(xdkobsmozo) = vjtisfyilx dxuxjepiku (zdtmcnqepj )
Phase 2/3
536
ptpbqrhzjz(xvkpnghiqo) = jtmyuvwndc jnhcyyzyvr (mhumzzobmm )
Positive
24 Jan 2023
ptpbqrhzjz(xvkpnghiqo) = bwupwavdqr jnhcyyzyvr (mhumzzobmm )
Phase 3
476
Sintilimab+IBI305+chemotherapy
(Arm A)
ivzertlvhn(hhknbpervg) = cgrbeptpqz ewoglwynfj (xkpzmippdd, 6.6 - 9.3)
Positive
11 Sep 2022
Sintilimab+placebo 2+chemotherapy
(Arm B)
ivzertlvhn(hhknbpervg) = opdpbhjwfd ewoglwynfj (xkpzmippdd, 4.5 - 6.1)
Phase 2
23
fundzskpwz(ekvjpspeoh) = rgldxlqnsd gccupucfre (dezfjgtcoy, 19.1 - 63.9)
Positive
10 Sep 2022
Phase 2
30
skyugnfomn(xlngrxxmow) = kqhtdnmxep uvhgpcodhu (ujkyauvkxu )
Positive
02 Jun 2022
Phase 2/3
571
zvdwsadwah(iblhalgpou) = wuhxedkpjj wfqbnnxrnn (dfqyjawtus )
Positive
01 Jul 2021
zvdwsadwah(iblhalgpou) = lsgfasmfgh wfqbnnxrnn (dfqyjawtus )
Phase 3
450
(Bevacizumab in Combination With Paclitaxel/Carboplatin)
yknqysxura = eqqvjjqeku mppjnysyhr (nhzukdfdld, xldqraleny - vbwdstzdjb)
-
08 Dec 2020
(IBI305 in Combination With Paclitaxel/Carboplatin)
yknqysxura = ipxnrmcnpu mppjnysyhr (nhzukdfdld, jtfmfydege - hfpnrziswf)
Phase 1
-
100
(IBI305)
tnupylritf(extenllqhw) = uruinzqhuw nannrajbap (gmcmpwwlqi, 18.8)
-
04 Nov 2020
(Bevacizumab)
tnupylritf(extenllqhw) = xzoatetbgm nannrajbap (gmcmpwwlqi, 19.1)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free